April 25, 2023
3 min watch
Save
VIDEO: Faricimab shows greater reduction in macular leakage vs. aflibercept in DME
Key takeaways:
- A study at the ARVO meeting discussed macular leakage in the YOSEMITE and RHINE studies.
- Faricimab resulted in a greater reduction in macular leakage compared with aflibercept.
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Roger A. Goldberg, MD, MBA, discusses results from the YOSEMITE and RHINE studies.
The trials compared aflibercept to faricimab for the treatment of diabetic macular edema.
“Faricimab did a better job at reducing macular leakage vs. aflibercept after four loading doses of both drugs,” Goldberg said.